On the stock market since 1987, it operates in the world of health and science. It has 8 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
No real growth (5% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades 33% below its peak. The market has trimmed its expectations for the company.
Sales run at $7.5M a year. A small number, but proof the product has real buyers.
There is $1.7M in the vault; even if every debt were paid off, $941K would remain.
A loss of $64K against $7.5M in annual sales.
On our five-subject report card, CMPD sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: CMPD is a high-risk stock — not yet profitable, and its future rides on its product catching on.